Kancera (KAN.ST) Stock Analysis & AI Equity Report
Kancera (KAN.ST) overview
Kancera (KAN.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Kancera reported revenue of SEK 0.0m and operating profit of SEK -46.2m; the year-end share price was 1.09 SEK and market capitalisation was SEK 126m. Kancera is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Kancera's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Kancera
Kancera AB (publ) is a clinical-stage biotechnology company developing small-molecule drugs that modulate immune-cell signaling, with a current focus on cardiovascular diseases. Its lead candidates include KAND567 and KAND145, which are being advanced through clinical and preclinical development. The company is also in the process of rebranding to Novakand Pharma as it sharpens its cardiovascular strategy.
Generate the Kancera report
Kancera is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Kancera and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.